Specific Subgroups of Patients with Metastatic Castration Resistant Prostate Cancer Live Longer with Talazoparib Added to their Enzalutamide Therapy

Audio Journal of Oncology Podcast

SAN FRANCISCO, CA—Adding the poly ADP ribose polymerase (PARP) inhibitor drug talazoparib to standard anti-androgen therapy with enzalutamide statistically significantly extended overall survival among patients whose metastatic castration resistant prostate cancers had specific molecular markers.

This finding was reported at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium held in San Francisco from the TALAPRO-2 phase three clinical trial investigating patients with or without homologous recombination repair (HRR) gene alterations.

The co-lead author of the study, Karim Fizazi MD PhD, Head of the Genitourinary Oncology Group at the Gustave Roussy Institute in Paris and Professor of Oncology at the Université Paris-Saclay in Paris, France, talked with Audio Journal of Oncology correspondent Peter Goodwin about the details of the findings and his clinical recommendations.